A recent meta-analysis study has indicated that metformin can give a better result when compared with the Sulfonylurea.
The risk of heart diseases will be lowered by about 30 to 40 percent. This drug works on the liver by lowering glucose output and by increasing glucose uptake in the muscle. This is the first drug for lowering glucose levels for the patients of type 2 diabetes (T2D).
Metformin is widely used for the treatment of diabetes and for weight loss. With Sulfonylurea, blood sugar (glucose) levels may go to very low levels and an increase in levels of insulin in the blood.
The study concluded that metformin can lower the lipids in the blood and can lower the risk of blood clot in the large blood vessels. But the drug will show a better result if it is used along with other weight loss treatment. The study was published in the Annals of Internal Medicine.
The Paula Carr Diabetes Trust, established in 1989 in memory of Paula Carr at Kent, is distributing the free information about diabetes across Kent and Medway. Patients can contact the charity trust.
Researchers have conducted a five-year pilot study in the United States. The study shows that elderly people have lost body weight and blood sugar (glucose) levels due to regular lifestyle counseling. Overall, more than 7,700 people have lost the body weight by more than five percent.
The people who recognize the signs of prediabetes can prevent it from becoming full diabetes with a daily exercise and lifestyle changes. If the person of pre-diabetes could not change his lifestyle, then there is a 15 to 30 percent chance of progression of pre-diabetes to full diabetes.
The amount of food a person is eating is important for the prevention of type 2 diabetes (T2D). Once the body fat exceeds the fat limit of the body, the excessive fat will not be stored under the skin. The excess fat will be stored in the important organs. One can notice the signs of type 2 diabetes (T2D) if the person.
Islexa was started by the Cell and Gene Therapy Catapult (CGT) and the University of Aberdeen, the United Kingdom. The company has developed new technology for the treatment of type 1 diabetes (T1D). This treatment can eliminate the use of insulin injections.
The new technology will turn the pancreas tissue from donors into fully functional islets. Islets are organoids found in our pancreas to secrete insulin. About 70 percent of the Islet cells are beta cells, which secretes insulin.
The company is planning to perform 50 islet transplants in a year. The pre-clinical study was a successful and clinical trial is expected in a couple of years. The report was published in the Journal of Clinical Investigation.
The Coronary Artery Risk Development in Young Adults study (CARDIA) was investigating a possible link between exercise and the risk of diabetes over the last 20 years. Total of 4,373 people enrolled in this study.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.